Transformative medicines are needed to prevent neurodegeneration in Alzheimer’s disease. Current therapies do not slow or stop the continued neurodegeneration that causes the progressive cognitive decline experienced by patients with Alzheimer’s. Moreover, decades of effort focused on neuron targeted therapies have yet to yield a significant disease modifying therapy. The complexity of Alzheimer’s disease necessitates pursuit of novel and alternative approaches to therapy. We are pursuing an exciting new approach to treating Alzheimer’s disease by targeting non-neuronal reactive glial cells. Recent studies have identified a prevalent pathological state of toxic reactive glia as a major contributor to neurodegeneration and disease progression. These toxic glia represent an unrealized opportunity as a cellular therapeutic target for Alzheimer’s disease. Our vision is to discover and advance new medicines that block the formation of toxic glia with the goal of protecting neurons and preventing or reversing disability in patients.